NovoCure Limited (038.F)
| Previous close | 11.23 |
| Open | 11.43 |
| Bid | 11.25 x 50000 |
| Ask | 11.48 x 40000 |
| Day's range | 11.43 - 11.43 |
| 52-week range | 10.08 - 78.30 |
| Volume | |
| Avg. volume | 35 |
| Market cap | 1.224B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.83 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 177.14 |
Business WireNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
ROOT, Switzerland, April 05, 2024--Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego.
ZacksNovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Business WireNovocure to Report First Quarter 2024 Financial Results
ROOT, Switzerland, April 01, 2024--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months ended March 31, 2024, at 8:00 a.m. EDT on Thursday, May 2, 2024. To access the conference call by phone, use the following conference call registration link and dial-in d
